| Psoriasis vulgaris
Cosentyx vs Otezla
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Cosentyx vs Otezla with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOtezla has a higher rate of injection site reactions vs Cosentyx based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Otezla but not Cosentyx, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cosentyx
Otezla
At A Glance
SC injection
Every 4 weeks
IL-17A antagonist
Oral
Once or twice daily
PDE4 inhibitor
Indications
- Psoriasis vulgaris
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Non-Radiographic Axial Spondyloarthritis
- Enthesitis-Related Arthritis
- Hidradenitis Suppurativa
- Arthritis, Psoriatic
- Psoriasis vulgaris
- Behcet Syndrome
Dosing
Psoriasis vulgaris 300 mg SC at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; 150 mg may be acceptable for some adults; pediatric patients 6 years and older receive weight-based dosing on the same schedule.
Arthritis, Psoriatic 150 mg SC with or without a loading dose at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; may increase to 300 mg SC every 4 weeks if active disease persists; IV option: 6 mg/kg loading at Week 0, then 1.75 mg/kg every 4 weeks infused over 30 minutes.
Ankylosing spondylitis 150 mg SC with or without a loading dose at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; may increase to 300 mg SC every 4 weeks if active disease persists; IV option: 6 mg/kg loading at Week 0, then 1.75 mg/kg every 4 weeks infused over 30 minutes.
Non-Radiographic Axial Spondyloarthritis 150 mg SC with or without a loading dose at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; IV option: 6 mg/kg loading at Week 0, then 1.75 mg/kg every 4 weeks infused over 30 minutes.
Enthesitis-Related Arthritis Weight-based SC dosing for pediatric patients 4 years and older at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; 150 mg for patients >= 50 kg.
Hidradenitis Suppurativa 300 mg SC at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; may increase to every 2 weeks in adults with inadequate response; pediatric patients 12 years and older receive weight-based dosing every 4 weeks.
Arthritis, Psoriatic, Psoriasis vulgaris, Behcet Syndrome Adults: OTEZLA 30 mg twice daily or OTEZLA XR 75 mg once daily orally after 5-day titration starting at 10 mg; reduce to 30 mg once daily in severe renal impairment (OTEZLA XR not recommended in severe renal impairment).
Arthritis, Psoriatic, Psoriasis vulgaris (pediatric >=6 years) Weighing >=50 kg: OTEZLA 30 mg twice daily or OTEZLA XR 75 mg once daily orally after weight-based titration; weighing 20 to <50 kg: OTEZLA 20 mg twice daily orally; reduce to once daily dosing in severe renal impairment.
Contraindications
- Previous serious hypersensitivity reaction to secukinumab or any excipient in COSENTYX
- Known hypersensitivity to apremilast or to any of the excipients in the formulation
Adverse Reactions
Most common (>=1%) nasopharyngitis, diarrhea, upper respiratory tract infection, rhinitis, oral herpes, pharyngitis, urticaria, rhinorrhea
Serious infections (including serious infections and sepsis), inflammatory bowel disease (Crohn's disease and ulcerative colitis), neutropenia, anaphylaxis, angioedema
Postmarketing anaphylaxis, angioedema, systemic vasculitis, eczematous eruptions, cutaneous vasculitis, pyoderma gangrenosum, opportunistic infections including esophageal candidiasis, cytomegalovirus gastroenteritis/colitis, Pneumocystis jiroveci pneumonia, hepatitis B virus reactivation, histoplasmosis, toxoplasmosis
Most common (>=2%) Diarrhea, nausea, headache, upper respiratory tract infection, vomiting, abdominal pain upper, nasopharyngitis
Serious Hypersensitivity, depression, weight decrease, severe worsening of psoriasis (rebound)
Pharmacology
Secukinumab is a human IgG1 monoclonal antibody that selectively binds to the IL-17A cytokine and inhibits its interaction with the IL-17 receptor, suppressing the release of proinflammatory cytokines and chemokines involved in inflammatory and immune responses.
Apremilast is an oral small molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP); PDE4 inhibition increases intracellular cAMP levels and reduces pro-inflammatory cytokines including IL-17, IL-22, and TNF-alpha in blood and skin.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cosentyx
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Otezla
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (9/12)
UnitedHealthcare
Cosentyx
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (1/8) · Qty limit (4/8)
Otezla
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (2/8) · Qty limit (8/8)
Humana
Cosentyx
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Otezla
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Ankylosing Spondylitis: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Cost estimate not availableAmgen Safety Net Foundation: Otezla
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CosentyxView full Cosentyx profile
OtezlaView full Otezla profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.